Transpire Bio’s ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
SUNRISE, Fla., May 11, 2026 (PR NEWSWIRE) — Transpire Bio Inc., an integrated clinical- stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of the high-strength Trelegy® Ellipta®1 (200 mcg/62.5 mcg/25 mcg) product, […]
Transpire Bio Announces Opening of New Satellite R&D Facility in Shanghai, China
SUNRISE, Fla., April 28, 2026 (PR Newswire) — Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, has opened its new satellite R&D facility in Shanghai, China. An opening ceremony was held on April 23, 2026, to inaugurate the site, with local Chinese authorities in attendance to commemorate […]
Transpire Bio Strengthens its Leadership Team with Appointment of Ewan Livesey as Head of Business Development
SUNRISE, FL; March 17, 2026 (GLOBE NEWSWIRE) — Transpire Bio Inc., a U.S. based, clinical-stage, revenue-generating biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of Ewan Livesey, as Head of Business Development. “As Transpire Bio continues to progress its pipeline of complex generics and innovative medicines, we […]
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) — Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane Clifton as Chief Financial Officer (CFO). “As Transpire Bio continues to progress from a clinical-stage to commercial-stage biopharmaceutical company, we are aligning […]
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of Trelegy® Ellipta®1 100/62.5/25, has been accepted for filing by the […]
Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
SUNRISE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Transpire Bio announced today that its Chief Executive Officer, Dr. Xian-Ming Zeng, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at 8:00 am Pacific Time. About Transpire Bio Inc. Transpire Bio Inc. is an integrated, US-based, revenue-generating, […]
Transpire Bio Announces Completion of First Human Dosing in Clinical Trial Using its Novel Inhalation Formulation
SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has successfully dosed the first human subject with its experimental drug candidate in a novel inhalation formulation. The initial clinical study is designed to evaluate pulmonary […]
Transpire Bio Manufacturing Facility Receives the Establishment Inspection Report Following a Pre-Approval Inspection by the U.S. FDA
SUNRISE, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that the U.S. FDA has completed a Pre-Approval Inspection (PAI) at its manufacturing facility in Weston, Florida, with a Voluntary Action Indicated (VAI) classification. The company has now […]
Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases
News US-Based Manufacturing US-Based Manufacturing TRB-ILD1 granted U.S. Orphan Drug Designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF) TRB-ONC1 granted U.S. Orphan Drug Designation by the FDA for the treatment of glioblastoma (GBM) SUNRISE, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused […]
Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA
News SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate and vilanterol inhalation powder, a generic version of Breo® Ellipta®1 100/25, has been accepted for filing by the U.S. […]